Additionally, a newly developed CXCR4 antagonist, PRX177561, has demonstrated a significant reduction in glioblastoma tumour growth and the potential to enhance the effects of anticancer chemotherapy and radiotherapy. Here, CXCR4 is linked to neoplasm.